TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06733038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg iv over 30 minutes (60 minutes at first infusion) day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg iv over 90 minutes at cycle 1 (if well tolerated, it is administered over 60 minutes at cycle 2, and over 30 minutes at cycle 3) day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan (CPT-11)
Description: 165 mg/sqm iv over 60 minutes day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: 165 mg/sqm iv over 60 minutes day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/sqm iv over 2 hours day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil (5-FU)
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1
Study: NCT06258291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemosystem REBOOT
Description: The HemoSystem REBOOT will selectively remove three mediators largely contributing to sepsis-induced immunosuppression, from extracorporeal circulation based on magnetic beads.
Study: NCT06342349

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza virus split vaccine (MDCK cells)
Description: Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza virus split vaccine (Chicken embryo)
Description: Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate buffer solution
Description: Phosphate buffer solution without vaccine antigen(0.5ml/dose).
Study: NCT06543290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Pill
Description: Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin Pill
Description: Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
Study: NCT04986969

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online cognitive behavioral therapy
Description: online cognitive behavioral therapy delivered using one of two active methods

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online cognitive behavioral therapy
Description: online cognitive behavioral therapy delivered using one of two active methods
Study: NCT06733038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: 3200 mg/sqm 48 h-continuous infusion, starting on day 1
Study: NCT06721156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: MK-1167 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: MK-1167 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: MK-1167 oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule
Study: NCT05347056

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar Spine Magnetic Resonance
Description: Metal artifact reduction sequence (mars), axial t2 sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Lumbar Spine Magnetic Resonance
Description: Metal artifact reduction sequence (mars), axial t2 sequence

Intervention type: DIAGNOSTIC_TEST
Intervention: Isokinetic trunk flexion-extension trunk muscle strength and endurance test
Description: To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s

Intervention type: DIAGNOSTIC_TEST
Intervention: Isokinetic trunk flexion-extension trunk muscle strength and endurance test
Description: To evaluate for trunk muscle strength and endurance angular velocity of 60 and 120°/s

Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Region Range of motion assessment
Description: To evaluate for lomber region ROM with digital inclinometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Region Range of motion assessment
Description: To evaluate for lomber region ROM with digital inclinometer

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiograph
Description: spinal radiograph AP/Lateral

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiograph
Description: spinal radiograph AP/Lateral

Intervention type: BEHAVIORAL
Intervention: SRS 22
Description: SRS-22 Patient Questionnaire

Intervention type: BEHAVIORAL
Intervention: SRS 22
Description: SRS-22 Patient Questionnaire
Study: NCT06477341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: various available nutrition as those contain high protein content as ensure milk
Description: note effect with usually prescribed suitable oral and parenteral nutrition for head and neck cancers receiving radiotherapy
Study: NCT06469775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity shock wave
Description: 6 sessions of low intensity shock wave therapy, applied in 15 minute appointments once weekly.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard of care treatment: phosphodiesterase 5 inhibitor therapy, vacuum erectile device, constriction bands, intracorporal injections, and penile implant.
Study: NCT03748563

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ds-MCE and EGD
Description: Procedure of ds-MCE:~The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows.~Procedure of EGD:~The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session.
Study: NCT04831385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: CBT is a first line therapy for insomnia
Study: NCT05590299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fish oral immunotherapy (codfish)
Description: Codfish in mixture of potato prepared under food manufacturing regulations provided in varying doses

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral immunotherapy
Description: Placebo in potato mixture prepared under food manufacturing regulations provided in varying doses
Study: NCT05102838

Intervention type: OTHER
Intervention: Anti-virus treatment
Description: Anti-virus treatment

Intervention type: OTHER
Intervention: Anti-virus treatment
Description: Anti-virus treatment

Intervention type: OTHER
Intervention: Anti-virus treatment
Description: Anti-virus treatment

Intervention type: OTHER
Intervention: Anti-virus treatment
Description: Anti-virus treatment
Study: NCT05841654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
Description: The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan or antihypertensive drugs other than ACEI, ARB or ARNI
Description: The patient's ECG information will be monitored through the ECG monitoring patch, and the time of the first atrial fibrillation event will be recorded. Monitoring whether the patient's blood pressure is controlled dynamically, using echocardiography to evaluate cardiac function, and using scales to assess the quality of life.
Study: NCT03828708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron in infant formula
Description: Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron in infant formula
Description: Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
Study: NCT04391270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended intervention
Description: A blended intervention group combining the web-based components with face-to-face workshops and posters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based intervention
Description: A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters
Study: NCT04727827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic-guided supportive care
Description: Patients undergoing hematopoietic stem cell transplantation will be genotyped and supportive care therapies tailored to identified drug-gene pairs and guideline recommendations
Study: NCT05157763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EscharEx 5% (EX-02 formulation)
Description: EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
Study: NCT04948632

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete LeoMed application
Description: Access to the complete LeoMed application on the participant's smartphone. The day before surgery, participants will receive notifications encouraging them to use the platform to help prepare for their surgery. Safety instructions will also be sent. Postoperatively, notifications will be sent to the participants every day during the first 4 days and on the 7th day. These notifications will direct them to online forms that aim to assess their condition. On the 15th and 30th postoperative day, the platform will send a follow-up form. The platform will collect this information and classify it for appropriate management of their condition.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Basic LeoMed application
Description: Access to a partial version of the LeoMed application on the patient's smartphone during a visit to the preoperative clinic. Before surgery, participants will receive a phone call to be summoned to the hospital and to remind them of the safety instructions. Postoperatively, their follow-up will not be standardized and will vary depending on their surgeon. On the 15th and 30th postoperative day, the platform will send a follow-up form. In the event of an emergency, they will receive the contact details of the CHUM Health Infoline to ensure the continuity of their care.
Study: NCT05877664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG0895 Hydrochloride for Injection
Description: The dose escalation of ZG0895.HCl is set as 0.06, 0.12, 0.18, 0.37, 0.75, 1.50, 2.25, 3.00, and 3.75 mg/m\^2 groups, subcutaneous (SC) injection once a week (QW)
Study: NCT05186298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ PanOptix®
Description: The AcrySof IQ PanOptix® (Alcon) mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synergy®
Description: The TECNIS Synergy™ IOLs mitigate the effects of presbyopia by providing far vision comparable to an aspheric monofocal IOL. Compared to an aspheric monofocal IOL, the lens provides significantly improved intermediate and near vision, including in low-light conditions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: IOL implantation will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: IOL implantation will be performed
Study: NCT05077449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3287+Fulvestrant
Description: XZP-3287 360 mg orally Twice daily(Q12H) of every 28-day cycle Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle (28-day) until progressive disease
Study: NCT05130021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: MAX-40279-01 50mg/70mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: MAX-40279-01 50mg/70mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279-01
Description: MAX-40279-01 50mg/70mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: regorafenib
Study: NCT05051085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered treatment: SpilleFri.
Description: The guided internet program consists of 8 modules over a period of 10 weeks. The content is written psychoeducation, videos with patients and experts, and exercises (encouraging reflection, cognitive restructuring, and exposure). The program is therapist-guided; hence all patients will receive support primarily from a specific therapist during the 10 weeks.
Study: NCT05328843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB119
Description: Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB119
Description: Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB119
Description: Each subject received only one dose of study drug during the study period. After completing the pre-dose procedure on the morning of the first day of the study, the subjects were given a subcutaneous injection of PB-119 0.3 mL (150 μg) once in the abdomen by the study nurse. The actual time of administration will be recorded in the subject's eCRF.~Subjects should remain on an empty stomach for at least 10 hours prior to administration.
Study: NCT05516095

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnet stimulation
Description: Theta burst stimulation, which is a form of Transcranial magnet stimulation, works by inducing focused magnetic field pulses to make durable changes in the activity of brain regions. The magnetic pulses are transferred to the brain through an electromagnetic coil.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Transcranial magnet stimulation
Description: Similar in appearance and give the same sound as the active device, but deliver no magnetic pulse that reach the brain
Study: NCT05832814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated training
Description: For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm. For singing training, patients follow the audios and videos to take training at home, which are recorded by singing teachers and physiotherapists prior to the trial. Each session includes technical instructions in order to achieve better respiratory control during singing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythm-guided exercise training
Description: For rhythm-guided walking exercise, the home exercise intensity, that is, the walking speed can be prescribed based on the incremental shuttle walking test(ISWT) result. A rhythm matching with the walking speed can be calculated. Then patients will be provided a group of melodies identified by the calculated rhythm, which are also popular with the elder. During exercise, the patients are required to walking on a fixed speed identical with the rhythm.
Study: NCT06295146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention A: 1-on-1 wheelchair skills training by a peer coach
Description: Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention A: 1-on-1 wheelchair skills training by a peer coach
Description: Trainees will engage in 1:1 virtual zoom meetings facilitated by the study team scheduled weekly for 6 sessions with the opportunity for 2 makeup sessions. Sessions will last approximately 30 minutes and may include goal setting, review of progress, instruction, and homework of prescribed content for trainees to review. Participants may upload videos of themselves completing skills through Qualtrics to get feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention B: Training via educational videos
Description: Intervention B will be a series of educational videos that participants review and then are encouraged to the practice the skills. Participants will have access to the materials for 8 weeks. Group 3 will have access to approximately 3 hours of wheelchair skills video training content. Actual viewing time will depend upon the individual's training goal. While they will receive a weekly reminder about practicing, there is no prescribed frequency for how often they should be practicing the skills in the videos.
Study: NCT06380530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deformity correction
Description: Surgeries to correct bone defomity, supported by the use of preoperative planning and/or patient-specific instruments
Study: NCT04745988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 20mg
Description: Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 8mg
Description: Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 50mg/m\^2 as a IV infusion, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 85mg/m\^2 as a IV infusion, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Levofolinate will be administered at a dose of 200mg/m\^2 as a IV infusion, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
Study: NCT06270290

Intervention type: OTHER
Intervention: Exposure to contact sports or history of concussions
Description: History of contact sports practices or of concussions

Intervention type: OTHER
Intervention: Exposure to contact sports or history of concussions
Description: History of contact sports practices or of concussions
Study: NCT06150014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide fumarate tablet
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
Study: NCT04797286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil 20 mg three times a day. This is the approved dose for the treatment of pulmonary arterial hypertension. It is being studied in this trial with a population who has mildly elevated pulmonary pressures.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral pill placebo.
Study: NCT06345781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abdominal Functional Electrical Stimulation
Description: Functional electrical stimulation electrodes will be applied to the abdomen during a bowel program to assess effects of stimulation on bowel management time.
Study: NCT06150014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir alafenamide fumarate tablet
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir alafenamide fumarate tablet
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir alafenamide fumarate tablet
Description: Tenofovir alafenamide fumarate inhibits hepatitis B virus replication.
Study: NCT06557577

Intervention type: OTHER
Intervention: No intervention group.
Description: There is no intervention group.
Study: NCT05995366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Solution; Oral